Hyperlipen

Ciprofibrate, the active ingredient in Hyperlipen, is a fibrate presented as an oral tablet for oral use. It is used to lower elevated blood lipids, particularly triglycerides, in adults with lipid disorders.

GNH USA supplies Hyperlipen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyperlipen (ciprofibrate) belongs to the fibrate class and is employed to manage disorders of lipid metabolism.

Hyperlipidemia: reduces total cholesterol and LDL‑cholesterol levels. Hypertriglyceridemia: lowers elevated plasma triglycerides. Mixed dyslipidemia: improves overall lipid profile by decreasing triglycerides and modestly raising HDL‑cholesterol.

Ciprofibrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal discomfort such as nausea or abdominal pain. - Elevated liver enzymes indicating mild hepatic stress. - Muscle aches or weakness, especially during physical activity. - Headache or dizziness.

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis, presenting as severe muscle pain and dark urine. - Significant hepatic injury with jaundice or hepatitis. - Gallstone formation due to altered cholesterol metabolism. - Severe allergic reactions including rash, swelling, or anaphylaxis.

Before initiating therapy with Hyperlipen, several safety considerations should be observed.

Liver function monitoring: assess baseline enzymes and repeat periodically. Renal function assessment: evaluate creatinine clearance in patients with kidney disease. Drug interactions: review concurrent medications that affect lipid metabolism. Pregnancy and lactation: avoid use unless clearly indicated by a physician. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Ciprofibrate can interact with other agents, requiring careful management.

Major Interactions (Avoid): - Statins (e.g., simvastatin, atorvastatin): increased risk of myopathy. - Anticoagulants (e.g., warfarin): potentiation of anticoagulant effect. - Gemfibrozil: additive risk of severe muscle toxicity.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: possible alteration of blood glucose control. - Thyroid hormones: may affect thyroid function tests. - Cyclosporine: potential increase in ciprofibrate plasma levels.